Somatostatin preserved blood brain barrier against cytokine induced alterations: Possible role in multiple sclerosis

Biochemical Pharmacology

Volumn 86, Issue 4, 2013, Pages 497-507

  Basivireddy, Jayasree ^a   Somvanshi, Rishi K ^a   Romero, Ignacio A ^b   Weksler, Babette B ^c   Couraud, Pierre Olivier ^d   Oger, Joel ^a   Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OPEN UNIVERSITY   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d INSTITUT COCHIN   (France)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Cytokines; Inflammation; Multiple sclerosis; Somatostatin

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN ZO1; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 4; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE CELL MEMBRANE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84884909588     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.06.001     Document Type: Article

References (43)

1. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68:S22-31. (Pubitemid 46848608)
2. Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 2011;585:3715-23.
3. Huang YM, Xiao BG, Ozenci V, Kouwenhoven M, Teleshova N, Fredrikson S, et al. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol 1999;99:82-90. (Pubitemid 29488572)
4. Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol 2010;229:180-91.
5. Kirk J, Plumb J, Mirakhur M, McQuaid S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003;201: 319-27. (Pubitemid 37258943)
6. Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007;33:86-98. (Pubitemid 46090313)
7. Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002;12:154-69. (Pubitemid 34259917)
8. Beal MF. Somatostatin in neurodegenerative illnesses. Metabolism 1990;39: 116-9. (Pubitemid 20286350)
9. Binaschi A, Bregola G, Simonato M. On the role of somatostatin in seizure control: clues from the hippocampus. Rev Neurosci 2003;14:285-301. (Pubitemid 37237196)
10. Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 1994;8:25-44. (Pubitemid 24024904)
11. Fox L, Alford M, Achim C, Mallory M, Masliah E. Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol 1997;56:360-8. (Pubitemid 27465018)
12. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98. (Pubitemid 29362641)
13. Patel YC, Murthy KK, Escher EE, Banville D, Spiess J, Srikant CB. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990;39:63-9. (Pubitemid 20286338)
14. Roca CA, Su TP, Elpern S, McFarland H, Rubinow DR. Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis. Biol Psychiatry 1999;46:551-6. (Pubitemid 29369083)
15. Sorensen KV. Somatostatin in multiple sclerosis. Acta Neurol Scand 1987;75: 161-7. (Pubitemid 17032666)
16. Blum AM, Metwali A, Mathew RC, Cook G, Elliott D, Weinstock JV. Granuloma T lymphocytes in murine schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN-gamma secretion. J Immunol 1992;149:3621-6.
17. Hayry P, Raisanen A, Ustinov J, Mennander A, Paavonen T. Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. FASEB J 1993;7:1055-60. (Pubitemid 23243449)
18. Brod SA, Hood ZM. Ingested (oral) SST inhibits EAE. Autoimmunity 2011;44: 437-43.
19. Muhvic D, Barac-Latas V, Rukavina D, Radosevic-Stasic B. Induction of experimental allergic encephalomyelitis in a low-susceptible Albino Oxford rat strain by somatostatin analogue SMS 201-995. Neuroimmunomodulation 2005;12:20-8. (Pubitemid 40528907)
20. Vockel M, Breitenbach U, Kreienkamp HJ, Brandner JM. Somatostatin regulates tight junction function and composition in human keratinocytes. Exp Dermatol 2010;19:888-94.
21. Pinter E, Helyes Z, Szolcsanyi J. Inhibitory effect of somatostatin on inflammation and nociception. Pharmacol Ther 2006;112:440-56. (Pubitemid 44508773)
22. Aguado-Llera D, Puebla-Jimenez L, Yebenes-Gregorio L, Arilla-Ferreiro E. Alteration of the somatostatinergic system in the striatum of rats with acute experimental autoimmune encephalomyelitis. Neuroscience 2007;148:238- 49. (Pubitemid 47211608)
23. Liew CW, Vockel M, Glassmeier G, Brandner JM, Fernandez-Ballester GJ, Schwarz JR, et al. Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions. FEBS Lett 2009;583:49-54.
24. Helyes Z, Pinter E, Sandor K, Elekes K, Banvolgyi A, Keszthelyi D, et al. Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice. Proc Natl Acad Sci U S A 2009;106:13088-93.
25. Gastambide F, Viollet C, Lepousez G, Epelbaum J, Guillou JL. Hippocampal SSTR4 somatostatin receptors control the selection of memory strategies. Psychopharmacology (Berl) 2009;202:153-63.
26. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998;282:737-40. (Pubitemid 28489384)
27. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005;19:1872-4. (Pubitemid 41598779)
28. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31. (Pubitemid 13158528)
29. Barros JC, Marshall CJ. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J Cell Sci 2005;118: 1663-71. (Pubitemid 40691894)
30. Fenyk-Melody JE, Garrison AE, Brunnert SR, Weidner JR, Shen F, Shelton BA, et al. Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene. J Immunol 1998;160:2940-6. (Pubitemid 28136750)
31. Sorensen KV, Christensen SE, Hansen AP, Ingerslev J, Pedersen E, Orskov H. The origin of cerebrospinal fluid somatostatin: hypothalamic or disperse central nervous system secretion. Neuroendocrinology 1981;32:335-8. (Pubitemid 11047647)
32. Wu H, Deng YY, Kang Y, Huang MH, Hu L, Tang CW. Clinical implication of blood somatostatin determination in critically ill patients. Chin Crit Care Med 2009;21:307-10.
33. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002;38:323-37. (Pubitemid 36398254)
34. Wang T-L, Yang Y-H. Role of Janus-associated kinases in somatostatin analog preconditioning of human umbilical-vein endothelial cells. J Acute Med 2011;1:17-22.
35. Helyes Z, Pinter E, Nemeth J, Sandor K, Elekes K, Szabo A, et al. Effects of the somatostatin receptor subtype 4 selective agonist J-2156 on sensory neuropeptide release and inflammatory reactions in rodents. Br J Pharmacol 2006;149:405-15. (Pubitemid 44582247)
36. Badway AC, West FM, Tente SM, Blake AD. Somatostatin regulates intracellular signaling in human carotid endothelial cells. Biochem Biophys Res Commun 2004;319:1222-7. (Pubitemid 38759541)
37. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec (Hoboken) 2009;292:1902-13.
38. Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A 2010;107: 2580-5.
39. Harper SJ, Wilkie N. MAPKs: new targets for neurodegeneration. Expert Opin Ther Targets 2003;7:187-200. (Pubitemid 36512020)
40. Mori T, Wang X, Aoki T, Lo EH. Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J Neurotrauma 2002;19:1411-9. (Pubitemid 35403670)
41. Zech JC, Pouvreau I, Cotinet A, Goureau O, Le Varlet B, de Kozak Y. Effect of cytokines and nitric oxide on tight junctions in cultured rat retinal pigment epithelium. Invest Ophthalmol Vis Sci 1998;39:1600-8. (Pubitemid 28361320)
42. Arebi N, Healey ZV, Bliss PW, Ghatei M, Van Noorden S, Playford RJ, et al. Nitric oxide regulates the release of somatostatin from cultured gastric rabbit primary D-cells. Gastroenterology 2002;123:566-76. (Pubitemid 34827200)
43. Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW. Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage. J Neuroimmunol 2004;151: 171-9. (Pubitemid 38624411)